| 產(chǎn)品編號 | bs-7779R-PE-Cy5 |
| 英文名稱1 | Rabbit Anti-BRD7/PE-Cy5 Conjugated antibody |
| 中文名稱 | PE-Cy5標(biāo)記的鼻咽癌相關(guān)轉(zhuǎn)錄調(diào)節(jié)蛋白抗體 |
| 別 名 | 75 kDa bromodomain protein; BP75; BRD 7; BRD7; BRD7_HUMAN; Bromodomain containing 7; bromodomain containing protein 7; Bromodomain-containing protein 7; CELTIX 1; CELTIX1; NAG4; Protein CELTIX-1. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 信號轉(zhuǎn)導(dǎo) 細(xì)胞周期蛋白 表觀遺傳學(xué) |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Dog, Pig, Cow, Rabbit, Sheep, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 74kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human BRD7 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: This gene encodes a protein which is a member of the bromodomain-containing protein family. The product of this gene has been identified as a component of one form of the SWI/SNF chromatin remodeling complex, and as a protein which interacts with p53 and is required for p53-dependent oncogene-induced senescence which prevents tumor growth. Pseudogenes have been described on chromosomes 2, 3, 6, 13 and 14. Alternative splicing results in multiple transcript variants. Function: Acts both as coactivator and as corepressor. May play a role in chromatin remodeling. Activator of the Wnt signaling pathway in a DVL1-dependent manner by negatively regulating the GSK3B phosphotransferase activity. Induces dephosphorylation of GSK3B at 'Tyr-216'. Down-regulates TRIM24-mediated activation of transcriptional activation by AR (By similarity). Transcriptional corepressor that down-regulates the expression of target genes. Binds to target promoters, leading to increased histone H3 acetylation at 'Lys-9' (H3K9ac). Binds to the ESR1 promoter. Recruits BRCA1 and POU2F1 to the ESR1 promoter. Coactivator for TP53-mediated activation of transcription of a set of target genes. Required for TP53-mediated cell-cycle arrest in response to oncogene activation. Promotes acetylation of TP53 at 'Lys-382', and thereby promotes efficient recruitment of TP53 to target promoters. Inhibits cell cycle progression from G1 to S phase. Subunit: Interacts with TRIM24, PTPN13 and DVL1. Identified in a complex with SMARCA4/BRG1, SMARCC1/BAF155, SMARCE1/BAF57, DPF2/BAF45D and ARID2, subunits of the SWI/SNF-B (PBAF) chromatin remodeling complex (By similarity). Interacts with IRF2 and HNRPUL1. Interacts (via N-terminus) with TP53. Interacts (via C-terminus) with EP300. Interacts with BRCA1. Interacts (via bromo domain) with histone H3 (via N-terminus) acetylated at 'Lys-14' (H3K14ac). Has low affinity for histone H3 acetylated at 'Lys-9' (H3K9ac). Has the highest affinity for histone H3 that is acetylated both at 'Lys-9' (H3K9ac) and at 'Lys-14' (H3K14ac). Has very low affinity for non-acetylated histone H3. Interacts (via bromo domain) with histone H4 (via N-terminus) acetylated at 'Lys-8' (H3K8ac) (in vitro). Subcellular Location: Isoform 2: Nucleus. Similarity: Contains 1 bromo domain. Database links: UniProtKB/Swiss-Prot: Q9NPI1.1 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. BRD7可能參與了基因轉(zhuǎn)錄調(diào)控,是一個核轉(zhuǎn)錄調(diào)節(jié)蛋白。經(jīng)研究發(fā)現(xiàn)BRD7可能是通過Ras/MEK/ERK和Rb/E2F兩條通路影響細(xì)胞周期的進程，使細(xì)胞停滯于G0/G1期，BRD7具有阻止細(xì)胞周期進程的作用。BRD7蛋白尤其是在鼻咽癌的發(fā)病過程中發(fā)揮了十分重要作用，BRD7基因的過表達(dá)可通過調(diào)節(jié)MAPK及Wnt信號通路抑制鼻咽癌的生長，并將鼻咽癌阻滯在G1/S期。 |
